Search research articles
Contact Us
Filters
Showing results (41-50 of 94) with videos related to
Page
of 10
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 26, 2010
Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans
J Matthew Reinersman, Melissa L Johnson, Gregory J Riely, et al.
Oncology and Therapy
|
October 11, 2025
The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast
Balazs Halmos, Narjust Florez, Sarah Goldberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2023
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01
Toshio Shimizu, Jacob Sands, Kiyotaka Yoh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 6, 2023
Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients
Cloud P Paweletz, Grace A Heavey, Yanan Kuang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2022
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced <i>KRAS</i><sup></sup> Solid Tumors (KRYSTAL-1)
Sai-Hong Ignatius Ou, Pasi A Jänne, Ticiana A Leal, et al.
The Lancet. Oncology
|
April 2, 2026
Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial
Melissa L Johnson, Manish R Patel, Gerald S Falchook, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 20, 2022
International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials
Matthew P Smeltzer, Giorgio V Scagliotti, Heather A Wakelee, et al.
The New England Journal of Medicine
|
February 25, 2026
Phase 1 Study of Rezatapopt, a p53 Reactivator, in <i>TP53</i> Y220C-Mutated Tumors
Ecaterina E Dumbrava, Geoffrey I Shapiro, Aparna R Parikh, et al.
Clinical Lung Cancer
|
August 19, 2020
Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508)
Jyoti D Patel, Ju-Whei Lee, David P Carbone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 29, 2024
Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update
Afshin Dowlati, Horst-Dieter Hummel, Stephane Champiat, et al.
Page
of 10
Search research articles
Search
Showing results (41-50 of 94) with videos related to
Sort By:
Page
of 10
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 26, 2010
Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans
J Matthew Reinersman, Melissa L Johnson, Gregory J Riely, et al.
Oncology and Therapy
|
October 11, 2025
The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast
Balazs Halmos, Narjust Florez, Sarah Goldberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2023
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01
Toshio Shimizu, Jacob Sands, Kiyotaka Yoh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 6, 2023
Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients
Cloud P Paweletz, Grace A Heavey, Yanan Kuang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2022
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced <i>KRAS</i><sup></sup> Solid Tumors (KRYSTAL-1)
Sai-Hong Ignatius Ou, Pasi A Jänne, Ticiana A Leal, et al.
The Lancet. Oncology
|
April 2, 2026
Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial
Melissa L Johnson, Manish R Patel, Gerald S Falchook, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 20, 2022
International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials
Matthew P Smeltzer, Giorgio V Scagliotti, Heather A Wakelee, et al.
The New England Journal of Medicine
|
February 25, 2026
Phase 1 Study of Rezatapopt, a p53 Reactivator, in <i>TP53</i> Y220C-Mutated Tumors
Ecaterina E Dumbrava, Geoffrey I Shapiro, Aparna R Parikh, et al.
Clinical Lung Cancer
|
August 19, 2020
Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508)
Jyoti D Patel, Ju-Whei Lee, David P Carbone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 29, 2024
Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update
Afshin Dowlati, Horst-Dieter Hummel, Stephane Champiat, et al.
Page
of 10